IMC Chicago
TEVA icon

IMC Chicago’s Teva Pharmaceuticals TEVA Stock Holding History

IMC Chicago’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.7M Sell
456,000
-484,400
-52% -$15.6M ﹤0.01% 1055
2025
Q4 		$29.3M Buy
940,400
+290,100
+45% +$7.15M 0.01% 674
2025
Q3 		$13.1M Buy
650,300
+86,200
+15% +$1.51M ﹤0.01% 1005
2025
Q2 		$9.45M Buy
564,100
+79,200
+16% +$1.28M ﹤0.01% 1037
2025
Q1 		$7.45M Sell
484,900
-1,140,200
-70% -$20.4M ﹤0.01% 1021
2024
Q4 		$35.8M Buy
1,625,100
+976,400
+151% +$17.8M 0.02% 426
2024
Q3 		$11.7M Sell
648,700
-14,800
-2% -$259K 0.01% 751
2024
Q2 		$10.8M Buy
663,500
+323,700
+95% +$4.99M 0.01% 760
2024
Q1 		$4.79M Sell
339,800
-95,100
-22% -$1.2M ﹤0.01% 988
2023
Q4 		$4.54M Sell
434,900
-23,600
-5% -$220K ﹤0.01% 918
2023
Q3 		$4.68M Buy
458,500
+341,700
+293% +$3.18M ﹤0.01% 756
2023
Q2 		$880K Sell
116,800
-90,600
-44% -$735K ﹤0.01% 1085
2023
Q1 		$1.84M Sell
207,400
-155,400
-43% -$1.54M ﹤0.01% 873
2022
Q4 		$3.31M Sell
362,800
-45,800
-11% -$400K 0.01% 704
2022
Q3 		$3.3M Buy
408,600
+60,400
+17% +$534K ﹤0.01% 651
2022
Q2 		$2.62M Sell
348,200
-22,400
-6% -$195K ﹤0.01% 649
2022
Q1 		$3.48M Sell
370,600
-187,300
-34% -$1.56M ﹤0.01% 632
2021
Q4 		$4.47M Buy
557,900
+101,000
+22% +$912K ﹤0.01% 640
2021
Q3 		$4.45M Buy
456,900
+120,200
+36% +$1.13M ﹤0.01% 644
2021
Q2 		$3.33M Sell
336,700
-26,000
-7% -$275K ﹤0.01% 668
2021
Q1 		$4.19M Sell
362,700
-33,100
-8% -$380K 0.01% 606
2020
Q4 		$3.82M Buy
395,800
+110,700
+39% +$1.06M ﹤0.01% 604
2020
Q3 		$2.57M Buy
285,100
+25,400
+10% +$269K ﹤0.01% 544
2020
Q2 		$3.2M Sell
259,700
-192,400
-43% -$2.18M 0.01% 457
2020
Q1 		$4.06M Buy
452,100
+84,500
+23% +$866K 0.01% 364
2019
Q4 		$3.6M Buy
367,600
+167,800
+84% +$1.5M 0.01% 402
2019
Q3 		$1.38M Sell
199,800
-30,100
-13% -$231K ﹤0.01% 522
2019
Q2 		$2.12M Buy
229,900
+151,800
+194% +$1.83M 0.01% 409
2019
Q1 		$1.23M Sell
78,100
-141,200
-64% -$2.49M ﹤0.01% 451
2018
Q4 		$3.38M Buy
+219,300
New +$4.5M 0.01% 260

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

IMC Chicago's TEVA Position: Q1 2026 in Review

IMC Chicago opened a new position in Teva Pharmaceuticals (TEVA) in Q1 2026: 89,569 shares worth $2.7M. The stake represents ﹤0.01% of the portfolio and ranks #2308 among its holdings. This is a return to the name: IMC Chicago previously reported a position in TEVA as recently as Q2 2025.

IMC Chicago first reported a position in TEVA in Q1 2019 and has held it in 18 quarters since. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • IMC Chicago held 89,569 shares of Teva Pharmaceuticals worth $2.7M as of Q1 2026.
  • Teva Pharmaceuticals was a new IMC Chicago position in Q1 2026.
  • Teva Pharmaceuticals made up ﹤0.01% of IMC Chicago's portfolio in Q1 2026, its #2308 holding.
  • IMC Chicago first reported a position in Teva Pharmaceuticals in Q1 2019 and has held it in 18 quarters since.
  • 650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on IMC Chicago's 13F filing for Q1 2026, filed 5 May 2026.